ALIMERA SCIENCES, INC.>>> (NASDAQ:ALIM) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
Inc. (the “Company”) held on November 16, 2016, the following
proposal was submitted to the stockholders of the Company:
Incorporation to increase the number of authorized shares of common
stock, par value $0.01 per share, from 100,000,000 shares to
150,000,000 shares.
definitive proxy statement on Schedule 14A filed with the
Securities and Exchange Commission on October 14, 2016.
8,135,593 shares of common stock underlying the Companys
outstanding Series A Preferred Stock (based on a deemed conversion
price of $2.95 per share), entitled to vote at the special meeting
of the stockholders, 47,669,447 shares, or approximately 65%, were
represented at the meeting in person or by proxy, constituting a
quorum. The number of votes cast for or against, as well as
abstentions in respect of the proposal is set forth below.
Company’s Restated Certificate of Incorporation to increase the
number of authorized shares of common stock, par value $0.01 per
share, from 100,000,000 shares to 150,000,000 shares. The votes
regarding this proposal were as follows:
|
Votes For
|
Votes Against
|
Votes Abstaining
|
|
41,605,113
|
6,046,627
|
17,707
|
About ALIMERA SCIENCES, INC.>>> (NASDAQ:ALIM)
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies. ALIMERA SCIENCES, INC.>>> (NASDAQ:ALIM) Recent Trading Information
ALIMERA SCIENCES, INC.>>> (NASDAQ:ALIM) closed its last trading session down -0.04 at 1.16 with 174,886 shares trading hands.
